Lineage Cell Therapeutics Company

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. The company is focused on developing new therapeutics for age-related degenerative disease. BioTime and its subsidiaries are developing OpRegenВ® (a cell-based therapy for age-related macular degeneration), therapies for cancer, and arthritis, respectively. Our subsidiary ReCyte Therapeutics is using proprietary technology to reverse the developmental aging of human cells to manufacture young vascular progenitors for the treatment of age-related vascular disease. Relatively near-term product development by BioTime and its subsidiaries include Renevia, a patented hyaluronan-based hydrogel device for cell delivery; PanC-Dx, a blood-based pan-cancer screening diagnostic; and re-starting the embryonic stem cell-based clinical trial for spinal cord injury that was originally begun by Geron, using the stem cell assets acquired from them in 2013. BioTime also markets an FDA-approved blood plasma expander called HextendВ®, which is currently marketed in collaboration with Hospira.

Investors

Founded Date: 1/1/1990
Total Funding: 72908804 USD
Investor Type: For Profit
Employee Number: 101-250
Funding Status: IPO
Number Of Exists: 101-250
Technology: Regenerative Medicine
Last Funding Type: Grant
Investors Number: 1
Last Funding Date: 2019-05-10
Industry: Cellular therapy
Headquarters: Carlsbad, California, United States
Estimated Revenue: Less than $1M
Register and Claim Ownership